IP Library › Granted Patent US 8,785,156
Granted Patent B2
US 8,785,156 · App. 13/685,924 · Granted Jul 22, 2014

TLE3 as a marker for chemotherapy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,785,156
App. No.
13/685,924
Granted
Jul 22, 2014
Kind
B2
Abstract

Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.

Claims (30)

1. A method of treating breast, lung or ovarian cancer in a patient comprising administering to the patient in need thereof a taxane, wherein the patient's cancer has been previously identified to express TLE3 polypeptide.

2. The method of claim 1 , wherein the patient's cancer is breast cancer.

3. The method of claim 2 , wherein the patient is triple negative for estrogen receptor, progesterone receptor, and HER-2 markers.

4. The method of claim 2 , wherein the taxane is paclitaxel.

5. The method of claim 2 , wherein the taxane is docetaxel.

6. The method of claim 1 , wherein the patient's cancer is lung cancer.

7. The method of claim 6 , wherein the taxane is paclitaxel.

8. The method of claim 6 , wherein the taxane is docetaxel.

9. The method of claim 1 , wherein the patient's cancer is ovarian cancer.

10. The method of claim 9 , wherein the taxane is paclitaxel.

11. The method of claim 9 , wherein the taxane is docetaxel.

12. A method of treating breast, lung, or ovarian cancer in a patient, wherein the cancer has been identified as positive for TLE3 polypeptide expression, the method comprising administering a taxane to the patient.

13. The method of claim 12 , wherein the cancer is breast cancer.

14. The method of claim 13 , wherein the patient is triple negative for estrogen receptor, progesterone receptor, and HER-2 markers.

15. The method of claim 13 , wherein the taxane is paclitaxel.

16. The method of claim 13 , wherein the taxane is docetaxel.

17. The method of claim 12 , wherein the cancer is lung cancer.

18. The method of claim 17 , wherein the taxane is paclitaxel.

19. The method of claim 17 , wherein the taxane is docetaxel.

20. The method of claim 12 , wherein the cancer is ovarian cancer.

21. The method of claim 20 , wherein the taxane is paclitaxel.

22. The method of claim 20 , wherein the taxane is docetaxel.

23. A method of treating breast cancer in a patient, wherein the patient is triple negative for estrogen receptor, progesterone receptor, and HER-2 markers and the cancer has been identified as positive for TLE3 polypeptide expression, the method comprising administering a taxane to the patient.

24. The method of claim 23 , wherein the taxane is paclitaxel.

25. The method of claim 23 , wherein the taxane is docetaxel.

26. A method of treating lung or ovarian cancer in a patient, wherein the cancer has been identified as positive for TLE3 polypeptide expression, the method comprising administering a taxane to the patient.

27. The method of claim 26 , wherein the taxane is paclitaxel.

28. The method of claim 26 , wherein the taxane is docetaxel.

29. The method of claim 26 , wherein the cancer is lung cancer.

30. The method of claim 26 , wherein the cancer is ovarian cancer.

Assignments (8)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jun 28, 2019
From: REGIONS BANK, AS COLLATERAL AGENT
To: CLARIENT DIAGNOSTIC SERVICES, INC.
Reel/Frame 049629/0243 →
RELEASE OF SECURITY INTEREST Recorded Dec 23, 2016
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: CLARIENT, INC.; CLARIENT DIAGNOSTIC SERVICES, INC.
Reel/Frame 040759/0857 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 23, 2016
From: CLARIENT DIAGNOSTIC SERVICES, INC.
To: REGIONS BANK, AS COLLATERAL AGENT
Reel/Frame 041182/0700 →
RELEASE OF SECURITY INTEREST Recorded Dec 22, 2016
From: AB PRIVATE CREDIT INVESTORS LLC, AS COLLATERAL AGENT
To: NEOGENOMICS LABORATORIES, INC.; NEOGENOMICS, INC.; CLARIENT, INC.; CLARIENT DIAGNOSTIC SERVICES, INC.; PATH LABS, LLC
Reel/Frame 040754/0293 →
SECURITY INTEREST Recorded Jan 5, 2016
From: NEOGENOMICS LABORATORIES, INC.; NEOGENOMICS, INC.; CLARIENT, INC.; CLARIENT DIAGNOSTIC SERVICES, INC.; PATH LABS, LLC
To: AB PRIVATE CREDIT INVESTORS LLC, AS COLLATERAL AGENT
Reel/Frame 037408/0921 →
SECURITY INTEREST Recorded Dec 30, 2015
From: CLARIENT, INC.; CLARIENT DIAGNOSTIC SERVICES, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 037386/0565 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2012
From: RING, BRIAN Z.; ROSS, DOUGLAS T.; SEITZ, ROBERT S.; BECK, RODNEY A.
To: APPLIED GENOMICS, INC.
Reel/Frame 029434/0034 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2012
From: APPLIED GENOMICS, INC.
To: CLARIENT DIAGNOSTIC SERVICES, INC.
Reel/Frame 029434/0061 →